19:11 , Apr 25, 2019 |  BC Week In Review  |  Clinical News

Viela publishes Phase Ib data for CD40L antagonist in RA

Viela said the highest two doses of VIB4920 (formerly MEDI4920) significantly reduced disease activity in a Phase Ib trial to treat rheumatoid arthritis. Data were published in Science Translational Medicine . Viela first reported data...
13:53 , Apr 1, 2019 |  BC Extra  |  Clinical News

Apexigen's CD40 agonist shows response in pancreatic cancer

Over half of metastatic pancreatic cancer patients treated with Apexigen's APX005M as part of a combination regimen that included Opdivo nivolumab had a response, suggesting that the combination along with SOC could provide a new...
13:59 , Mar 27, 2019 |  BC Extra  |  Company News

Lilly, ImmuNext in preclinical autoimmune pact

ImmuNext granted Lilly an exclusive, worldwide license to an undisclosed preclinical target to treat autoimmune diseases. The partners said they intend to develop an antibody targeting the metabolism of lymphocytes. ImmuNext Inc. (Lebanon, N.H.) will...
22:22 , Mar 18, 2019 |  BC Extra  |  Company News

Astellas adds more drug delivery tech via NapaJen deal

Astellas has completed a second deal for a drug delivery technology, this time with NapaJen, that stands to add a new modality to its pipeline. Astellas Pharma Inc. (Tokyo:4503) will use oligonucleotide delivery technology from...
20:07 , Mar 13, 2019 |  BC Extra  |  Financial News

BioNTech mum on $800M IPO report

Amid a report that it will seek an $800 million IPO, BioNTech told BioCentury it is still evaluating all financial options. Citing undisclosed people familiar with the IPO, Reuters has reported that BioNTech AG (Mainz,...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
00:33 , Jan 25, 2019 |  BC Week In Review  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18 by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
00:30 , Jan 19, 2019 |  BC Extra  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Organ transplant rejection Mouse studies suggest inhibiting CXCL13, CD40L and ICOSLG, which play roles in B cell maturation and activation, could help treat antibody-mediated lung transplant rejection. In a mouse model of antibody-mediated lung...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...